Journal of Thoracic Oncology最新文献

{"title":"In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC","authors":"Qian Yan MD, Jinlin Liu MD, PhD","doi":"10.1016/j.jtho.2025.03.035","DOIUrl":"10.1016/j.jtho.2025.03.035","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Pages e86-e87"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144548361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decision Trees and Random Forests: Nonlinear and Nonparametric Alternatives to Logistic Regression in Biological Data Analysis","authors":"Yoshiyasu Takefuji PhD","doi":"10.1016/j.jtho.2025.03.003","DOIUrl":"10.1016/j.jtho.2025.03.003","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Pages e84-e85"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144549076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can a High-Dose of Furmonertinib Effectively Address Unmet Needs in EGFR-Mutated NSCLC with Leptomeningeal Metastases?","authors":"Jiawen Bu MD, PhD, Tong Zhu MD, Xudong Zhu MD, PhD","doi":"10.1016/j.jtho.2025.03.002","DOIUrl":"10.1016/j.jtho.2025.03.002","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Pages e80-e81"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144549125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Camrelizumab Plus Chemotherapy With or Without Radiotherapy Effective in NSCLC With Brain Metastases?","authors":"Guntulu Ak MD, PhD , Selma Metintas MD, PhD , Muzaffer Metintas MD","doi":"10.1016/j.jtho.2025.03.036","DOIUrl":"10.1016/j.jtho.2025.03.036","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Pages 829-830"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144549174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tobacco News Update—From the IASLC Tobacco Control Committee","authors":"","doi":"10.1016/j.jtho.2025.05.013","DOIUrl":"10.1016/j.jtho.2025.05.013","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Pages 823-825"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NSCLC Immunogenomics in People Living With HIV: Details Make the Difference","authors":"Sara Pilotto PhD , Umberto Malapelle PhD","doi":"10.1016/j.jtho.2025.03.032","DOIUrl":"10.1016/j.jtho.2025.03.032","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Pages 826-828"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144549164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meeting Announcements","authors":"","doi":"10.1016/S1556-0864(25)00731-2","DOIUrl":"10.1016/S1556-0864(25)00731-2","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Page A4"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144549171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The International Association for the Study of Lung Cancer Staging Project: The Database and Proposal for the Revision of the Staging of Pulmonary Neuroendocrine Carcinoma in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer","authors":"Ming Sound Tsao MD, FRCPC ,&nbsp;Adam Rosenthal MSc ,&nbsp;Andrew G. Nicholson DM, FRCPath ,&nbsp;Frank Detterbeck MD ,&nbsp;Wilfried E.E. Eberhardt MD ,&nbsp;Yolande Lievens MD ,&nbsp;Eric Lim MD ,&nbsp;Jose-Maria Matilla MD ,&nbsp;Yasushi Yatabe MD, PhD ,&nbsp;Pier Luigi Filosso MD ,&nbsp;Ricardo Beyruti MD ,&nbsp;Katherine K. Nishimura PhD, MPH ,&nbsp;William D. Travis MD ,&nbsp;Raymond Uyiosa Osarogiagbon M.B.B.S., FACP ,&nbsp;Ramon Rami-Porta MD ,&nbsp;Valerie Rusch MD ,&nbsp;Hisao Asamura MD, PhD ,&nbsp;Members of the IASLC Staging and Prognostic Factors Committee, the Advisory Boards, and Participating Institutions","doi":"10.1016/j.jtho.2025.01.013","DOIUrl":"10.1016/j.jtho.2025.01.013","url":null,"abstract":"<div><h3>Introduction</h3><div>Pulmonary high-grade neuroendocrine carcinoma (NEC) includes SCLC and large cell NEC (LCNEC). The seventh and eighth editions of the TNM classification for lung cancer confirmed the applicability of this staging system for SCLC. With the proposal of N2 and M1c subcategories for the ninth edition classification, we assessed the applicability to NECs.</div></div><div><h3>Methods</h3><div>The database included NEC cases diagnosed between January 2011 and December 2019. Eligible cases, with valid survival time and eighth edition TNM stage, were classified as pure SCLC, combined SCLC with NSCLC, and LCNEC. Survival was calculated using the Kaplan-Meier method, pairwise differences using a log-rank test, and prognostic groups using a Cox regression analysis.</div></div><div><h3>Results</h3><div>There were 6181 pure and combined SCLC and 697 LCNEC cases available. For SCLC, survival outcome analyses included 4453 cases with clinical stage and 583 with pathologic stage data. The corresponding numbers for LCNEC were 585 and 508. The SCLC data validated the ninth edition classification for lung cancer, including the proposed new subcategories, N2a, single-station ipsilateral mediastinal or subcarinal lymph node involvement, and N2b, involvement of multiple ipsilateral or subcarinal stations. The data also validated the subcategorization of M1c into M1c1 (multiple lesions in a single extrathoracic organ system) and M1c2 (involvement of multiple extrathoracic organ systems). The LCNEC data were insufficient for complete survival analysis, but the available data reported decreasing survival with increasing clinical and pathologic stages.</div></div><div><h3>Conclusions</h3><div>The ninth edition TNM classification applies to patients with NEC and is the appropriate standard for use in clinical practice.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Pages 856-870"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overdiagnosis of Lung Cancer Due to the Introduction of Low-Dose Computed Tomography in Average-Risk Populations in the People’s Republic of China","authors":"Dongchen Xie MD ,&nbsp;Li Zhang MD ,&nbsp;Na He MD, PhD ,&nbsp;Chen Yang MD ,&nbsp;Ruoxin Zhang MD, PhD ,&nbsp;Haiquan Chen MD, PhD ,&nbsp;Xing Liu MD, PhD ,&nbsp;Chen Suo MD, PhD ,&nbsp;Mengyan Wang MD ,&nbsp;Yan Wei MD, PhD ,&nbsp;Lipeng Hao BD ,&nbsp;Wanghong Xu MD, PhD","doi":"10.1016/j.jtho.2025.02.013","DOIUrl":"10.1016/j.jtho.2025.02.013","url":null,"abstract":"<div><h3>Introduction</h3><div>Low-dose computed tomography (LDCT) has been widely used in health check-ups in China since 2011. The introduction of LDCT in average-risk populations may have led to substantial overdiagnosis of lung cancer.</div></div><div><h3>Methods</h3><div>This registry-based study included 46,978 incident cases and 34,475 deaths of lung cancer derived from a population of approximately 3.21 million in the Pudong New Area of Shanghai, People’s Republic of China, from 2002 to 2020. We calculated the age-standardized rates of overall, stage- and histology-specific incidence and overall mortality by sex. The numbers and proportions of cases attributable to overdiagnosis were estimated on the basis of the comparison between the shape of the age-specific curve with that before the introduction of LDCT in average-risk populations since 2011.</div></div><div><h3>Results</h3><div>The age-standardized incidence of lung cancer increased rapidly since 2011 in both male and female individuals, whereas the age-standardized mortality declined over the period. The upward trends in incidence were mainly observed in women with early-stage cancer and lung adenocarcinoma. Overall, no significant overdiagnosis was observed in men, whereas the overdiagnosis rate grew from 22% in 2011 to 2015 to 50% in 2016 to 2020 in women. Further analysis reported elevated numbers (proportions) of lung adenocarcinoma cases attributable to overdiagnosis, which rose from 182 cases (8%) in 2011 to 2015 to 827 cases (22%) in 2016 to 2020 in men, and from 1842 cases (85%) to 4171 cases (89%) in women.</div></div><div><h3>Conclusion</h3><div>This study demonstrates considerable and increasing overdiagnosis of lung adenocarcinoma in Chinese men and women. The guideline is urgently needed to maximize the benefits of LDCT screening and reduce the potential overdiagnosis of lung cancer.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Pages 884-896"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reducing Lung Cancer Mortality by Providing Smoking Cessation Support in the Lung Cancer Screening Setting: Missed Opportunities and Lessons Learned on Both Sides of the Atlantic","authors":"Kathryn L. Taylor PhD ,&nbsp;Randi M. Williams PhD ,&nbsp;Rafael Meza PhD ,&nbsp;Pamela Smith PhD ,&nbsp;Rachael L. Murray PhD","doi":"10.1016/j.jtho.2025.03.030","DOIUrl":"10.1016/j.jtho.2025.03.030","url":null,"abstract":"<div><div>National guidelines for the implementation of lung cancer screening (LCS) for high-risk older adults have been issued by several countries, largely in Europe, North America, and Australia. Typically, these guidelines recommend but do not specify how smoking cessation support (SCS) should be provided to patients undergoing LCS who currently smoke. As LCS implementation progresses, delivering screening to the millions of eligible individuals around the world, the lack of best practice guidelines for SCS in the LCS setting is resulting in a growing missed opportunity to reduce persistent tobacco and lung cancer-related disparities in incidence and mortality.</div><div>Quitting smoking at older ages reduces lung cancer risk and increases life expectancy. Compelling evidence from clinical trials and modeling studies has shown that, even with modest cessation rates, SCS delivered in the LCS setting can considerably reduce lung cancer mortality, with the potential to reduce global, racial, economic, and geographic disparities in lung cancer. Moreover, SCS interventions are cost-effective and can lead to significant cost savings for the health system.</div><div>On the basis of the evidence and lessons learned in the United Kingdom, Canada, and the United States, we propose a set of priorities for health systems to consider when developing or expanding SCS programs in the LCS setting. We argue that the system and policy changes needed to maintain SCS as a standard component of LCS are essential to capitalize on this important opportunity to integrate disease prevention with early detection, thereby maximizing the mortality benefit of LCS worldwide.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Pages 847-855"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144549177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}